Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IN-C009
- Development stage
- Phase 1
- Lead developer
- HK inno.N Corporation
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
IN-C009 is an oral fixed-dose combination tablet containing **dapagliflozin 10 mg** and **linagliptin 5 mg**, developed by HK inno.N for type 2 diabetes mellitus. Dapagliflozin selectively inhibits sodium-glucose cotransporter 2 in the kidney, increasing urinary glucose excretion, while linagliptin reversibly inhibits dipeptidyl peptidase 4, prolonging endogenous incretin activity and enhancing glucose-dependent insulin secretion. A randomized crossover pharmacokinetic study in healthy adults found that the fixed-dose product had pharmacokinetic exposure comparable to co-administered individual dapagliflozin and linagliptin tablets and was safe and tolerable. ([mdpi.com](https://www.mdpi.com/1999-4923/14/3/591))
- Other names
- dapagliflozin + linagliptindapagliflozin/linagliptin
02
Targets
DPP-4 (Dipeptidyl Peptidase-IV)SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on IN-C009.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IN-C009.